single-cell genomics

Fluidigm has released a system and protocols to automate the processing of cells for single-cell transcriptome sequencing.

Fluidigm said this week that single-cell genomics and production genotyping continued to be the most important end markets for its gene expression products, helping to drive a 31 percent increase in product revenues amid an overall 22 percent revenue increase in the second quarte

Fluidigm said today that it has initiated an early-access program for its new C1 Single-Cell AutoPrep System for single-cell gene expression studies.

Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market

This article has been updated from a previous version to include market research information about Fluidigm from DeciBio.

Just ahead of announcing its first-quarter financial results, Fluidigm this week disclosed the end of one partnership and the beginning of another, with the net result being a de-emphasis of its digital PCR technology for molecular diagnostics and a continued emphasis on single-c

By Molika Ashford

By Ben Butkus

By Ben Butkus